Trial ID or NCT#
NCT01146054
Status
Purpose
This multi-institutional trial aims to evaluate the potential benefit and side effects of adding fractionated stereotactic body radiotherapy/surgery (SBRT) before and after chemotherapy with gemcitabine for locally advanced pancreatic cancer.
Official Title
Phase II Multi-Institutional Study to Evaluate the Efficacy of Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Investigator(s)
George A. Fisher Jr.
Medical oncologist,
Gastrointestinal specialist
Colleen Haas Chair in the School of Medicine
Jeffrey Norton, MD
Brendan C. Visser, MD
Hepatobiliary surgeon,
Pancreatic surgeon
Associate Professor of Surgery (General Surgery)
Contact us to find out if this trial is right for you.
CONTACT
Ccto-office@stanford.edu
(650) 498-7061
View on ClinicalTrials.gov